BioSpace News Archive

TELA Bio, Inc. (“TELA Bio”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report 2020 second quarter financial results on August 12, 2020. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial r

Study suggests GenScript’s cPass™ test is faster, better and safer than traditional tests

The U.S. Food and Drug Administration today announced it is requiring that labeling for opioid pain medicine and medicine to treat opioid use disorder (OUD) be updated to recommend that as a routine part of prescribing these medicines, health care professionals should discuss the availability of naloxone with patients and caregivers

Inotrem S.A. announced that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.

Midatech announces it has terminated the formal sale process initiated by the Company on 20 April 2020.

Opthea Limited, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce that clinical trial results from the Phase 1b/2a study of OPT-302 in diabetic macular edema patients refractory to anti-VEGF-A therapy, will be presented at the upcoming American Society of Retina Specialists Annual 2020 Virtual Annual Meeting.

RNA-based biopharmaceuticals is a comparatively new class of treatment and it comprises vaccines and therapeutics.

Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders, announced the appointment of Alan Buckler, Ph.D., as its chief scientific officer.